Buy Lupin, target price Rs 1100: Emkay Global
Lupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 36549.22 Crore) operating in Pharmaceuticals sector.
Lupin Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Other Operating Revenue and Other Services for the year ending 31-Mar-2021.
Financials
For the quarter ended 31-12-2021, the company reported a Consolidated Total Income of Rs 4194.99 Crore, up .74 % from last quarter Total Income of Rs 4164.14 Crore and up 3.87 % from last year same quarter Total Income of Rs 4038.53 Crore. Company reported net profit after tax of Rs 549.06 Crore in latest quarter.
Investment Rationale
The brokerage maintains Buy rating on the stock but lower the TP to Rs1,100 from Rs1,150 as it cuts earnings estimates for FY23/24 by 4% each. It also reduces FY22/23/24 EBITDA estimates by 7%/3%/3%, as the margin expansion seems delayed and linked to gSpiriva and gSuprep.
Promoter/FII Holdings
Promoters held 46.81 per cent stake in the company as of 31-Dec-2021, while FIIs owned 15.28 per cent, DIIs 24.83 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.